KR20230002589A - 장기 손상의 예방 및 치료 - Google Patents

장기 손상의 예방 및 치료 Download PDF

Info

Publication number
KR20230002589A
KR20230002589A KR1020227038978A KR20227038978A KR20230002589A KR 20230002589 A KR20230002589 A KR 20230002589A KR 1020227038978 A KR1020227038978 A KR 1020227038978A KR 20227038978 A KR20227038978 A KR 20227038978A KR 20230002589 A KR20230002589 A KR 20230002589A
Authority
KR
South Korea
Prior art keywords
infection
compound
damage
respiratory
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227038978A
Other languages
English (en)
Korean (ko)
Inventor
칭-퐁 막
파슈 마
동 샤오
마이클 필
한스 플리리
Original Assignee
파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드 filed Critical 파사이트 메디컬 테크놀로지 (상하이) 컴퍼니 리미티드
Publication of KR20230002589A publication Critical patent/KR20230002589A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020227038978A 2020-04-15 2021-04-15 장기 손상의 예방 및 치료 Pending KR20230002589A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/084820 2020-04-15
CN2020084820 2020-04-15
CNPCT/CN2021/081574 2021-03-18
CN2021081574 2021-03-18
PCT/CN2021/087501 WO2021209003A1 (en) 2020-04-15 2021-04-15 Prevention and treatment of organ injuries

Publications (1)

Publication Number Publication Date
KR20230002589A true KR20230002589A (ko) 2023-01-05

Family

ID=78085285

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227038978A Pending KR20230002589A (ko) 2020-04-15 2021-04-15 장기 손상의 예방 및 치료

Country Status (9)

Country Link
US (1) US12465629B2 (cg-RX-API-DMAC7.html)
EP (1) EP4135743A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521161A (cg-RX-API-DMAC7.html)
KR (1) KR20230002589A (cg-RX-API-DMAC7.html)
CN (2) CN114245744A (cg-RX-API-DMAC7.html)
AU (1) AU2021256222A1 (cg-RX-API-DMAC7.html)
CA (1) CA3174545A1 (cg-RX-API-DMAC7.html)
TW (1) TWI889805B (cg-RX-API-DMAC7.html)
WO (1) WO2021209003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
FI111730B (fi) 1990-11-02 2003-09-15 Novartis Ag Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi
JPH08298986A (ja) * 1995-04-28 1996-11-19 Asahi Chem Ind Co Ltd ホスホリパーゼa2酵素
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
ATE254630T1 (de) 1998-06-12 2003-12-15 Chem Ag C Cyclosporine
CN101068829B (zh) 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
PT1802650E (pt) * 2004-10-01 2011-12-30 Scynexis Inc Derivados da ciclosporina 3-éter e 3-tioéter substituída para o tratamento e prevenção da infecção de hepatite c
WO2007041632A2 (en) * 2005-09-30 2007-04-12 Scynexis, Inc. Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection
BRPI0708424A2 (pt) 2006-03-02 2011-05-31 Alexion Pharma Inc prolongamento da sobreviência de uma aloenxerto por inibição da atividade do complemento
CA2652662C (en) * 2006-05-19 2015-11-03 Scynexis, Inc. Methods for the treatment and prevention of ocular disorders
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes
US8536114B2 (en) 2008-12-31 2013-09-17 Scynexis, Inc. Macrocycles
US9217015B2 (en) 2010-07-16 2015-12-22 S&T Global Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
MX350746B (es) * 2010-12-03 2017-09-14 Hebei Kunxiangjishi Pharmaceutical Tech Co Ltd Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
GB201217560D0 (en) 2012-10-02 2012-11-14 Mitopharm Ltd Novel cyclic depsipeptide compounds and their uses
TW201639873A (zh) 2015-01-08 2016-11-16 歐樂根公司 Mebmt側鏈已環化之環孢菌素衍生物
CN105983095B (zh) * 2015-02-15 2019-09-13 艾棣维欣(苏州)生物制药有限公司 一种呼吸道合胞体病毒疫苗及其制备方法与应用
CN106902346A (zh) 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 药物组合物及其制药用途
CN106902347A (zh) * 2015-12-23 2017-06-30 中美华世通生物医药科技(武汉)有限公司 亲环孢素抑制剂的用途
GB201711749D0 (en) * 2017-07-21 2017-09-06 Cypralis Ltd Cyclosporin analogues and uses thereof
CN111449050A (zh) 2019-01-20 2020-07-28 睿诺医疗科技(上海)有限公司 环孢菌素类似物及其用途
CN116870135A (zh) * 2019-10-12 2023-10-13 睿诺医疗科技(上海)有限公司 肾毒素诱发的肾损伤的治疗和预防
CA3172535A1 (en) 2020-03-26 2021-09-30 Ching-Pong Mak Cyclophilin inhibitors and uses thereof
WO2021190603A1 (en) 2020-03-26 2021-09-30 Farsight Medical Technology (Shanghai) Co., Ltd. Cyclophilin inhibitors and uses thereof

Also Published As

Publication number Publication date
TW202143995A (zh) 2021-12-01
CA3174545A1 (en) 2021-10-21
CN113694177B (zh) 2022-06-17
AU2021256222A1 (en) 2022-10-06
EP4135743A4 (en) 2024-05-22
CN113694177A (zh) 2021-11-26
US20230181680A1 (en) 2023-06-15
WO2021209003A1 (en) 2021-10-21
EP4135743A1 (en) 2023-02-22
TWI889805B (zh) 2025-07-11
US12465629B2 (en) 2025-11-11
CN114245744A (zh) 2022-03-25
JP2023521161A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
CA3131137C (en) Methods of treatment of respiratory disorders
US20250025444A1 (en) Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor
TWI889805B (zh) 器官損傷的預防和治療
EP2608783A1 (en) Use of glycyrrhetinic acid, glycyrrhizic acid and related compounds for prevention and/or treatment of pulmonary fibrosis
CA2894466A1 (en) Uses and methods for the treatment of liver diseases or conditions
CN118806741A (zh) 二氢青蒿酸在制备预防或治疗急性肺损伤的药物中的应用
US20240277637A1 (en) Capsaicin derivatives in the treatment of idiopathic pulmonary fibrosis
CZ296396B6 (cs) Nová kombinace loteprednolu a agonistu beta2-adrenoceptoru
CN114053305B (zh) 无细胞脂肪提取液对肺部疾病的治疗用途
KR20180065224A (ko) 폐섬유증의 치료 또는 완화용 약학 조성물
AU2010322066A1 (en) Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
AU2022213291B2 (en) Lipids that reduce lung damage, improve pulmonary function and decrease pro-inflammatory cytokines
RU2451507C2 (ru) Лекарственное средство для лечения хронического обструктивного заболевания легких
CN111000847A (zh) 一种治疗肺纤维化的药物制剂及其用途
ES2938574T3 (es) Péptido para la prevención o el tratamiento de la COVID-19
TW202504602A (zh) 用於治療臟器纖維化相關疾病的藥物組合物和方法
WO2021185746A1 (en) Compounds for use in treatment of respiratory disease
JP2019511556A (ja) イソグリチルリチン酸またはその塩の吸入製剤および呼吸器疾患を治療する薬物の製造におけるそれらの応用
EP4709379A1 (en) Nmdar antagonist for the treatment of inflammatory diseases in patients with depression comorbidity
KR101969451B1 (ko) 만성 호흡기 질환 치료제 및 만성 호흡기 질환의 예방 또는 개선용 식품 조성물.
KR20180065223A (ko) 천식의 치료 또는 완화용 약학 조성물
JP2016027032A (ja) 慢性閉塞性肺疾患治療剤
Qian et al. Effects of intraperitoneal (IP) different doses of ketamine on cognitive function in aged rats: 9AP6-8
KR20130038583A (ko) 소포체 스트레스 억제제를 유효성분으로 함유하는 급성 폐 손상의 예방 또는 치료용 약학 조성물
Dal Negro et al. Use of aerosols in bronchiectasis patients

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000